Sponsored by the NTH and NIAID, and conducted by the ITN (Immune Tolerance Network), studies involving HDIT/HCT are showing significant progress in the potential treatment of MS, which show that immunosuppressive therapies in high doses when leading before the blood-forming stem cells transplantation of the patient can result in the tenable remission of multiple sclerosis when it is of relapsing-remitting nature.
At the moment, the studies have sustained five years of in-depth research including one pool of a volunteer-based trial consisting of individuals forgoing their typical MS medications to experience the new drug. Including 69% of these patients seeing no progression of the MS along with no signs of furthering symptoms, brain lesions, nor relapse, these results show a promising future for the treatment of MS.
With plans to engage larger studies in the near future, HDIT/HCT has the potential to become a seriously viable option for the sincere treatment of relapsing-remitting MS through its ability to actively restrain the disease while simultaneously ridding the body of diseased and disease-causing cells before rebooting the patient’s immune system.
Dr. Shiva Gopal Vasishta is among the brilliant doctors leading the charge in these researches. Focusing his career out of Voorhees, NJ, Dr. Shiva Gopal Vasishta is an expert in Neurology as well as Psychiatry and has devoted much of his life to the betterment of mental and neurological health. With 40 years of experience in his field, Dr. Shiva Gopal Vasishta is amongst the best in his field.
Working for Kennedy University Hospital as one of the 34 MDs at the outstanding hospital, Dr. Shiva Gopal Vasishta is taking great strides to gain admiration and respect through his unyielding hard work and dedication in respects of finding sustainable treatments and eventual cures for MS and other diseases.